Sandset Per Morten, Høibraaten Else, Eilertsen Anette Løken, Dahm Anders
Oslo University Hospital at Ullevål, Department of Hematology, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
Thromb Res. 2009;123 Suppl 2:S70-3. doi: 10.1016/S0049-3848(09)70015-5.
Combined oral contraceptives and combined oral postmenopausal hormone therapy are associated with a weak, but clinically significant risk of arterial and venous thrombosis (VT). The effects are related to dose of estrogen and type of progestin. The main effects are increase in markers of activated coagulation, reduction in coagulation inhibitors, and acquired activated protein C resistance. Reduction in tissue factor pathway inhibitor (TFPI) is probably an important mechanism, which predicts activation of coagulation and acquired resistance to activated protein C. Coagulation markers should be used as intermediate or surrogate markers in early pharmacodynamic studies to evaluate the risk associated with new formulations.
复方口服避孕药和复方口服绝经后激素疗法与动脉和静脉血栓形成（VT）的风险相关，这种风险虽小，但具有临床意义。其影响与雌激素剂量和孕激素类型有关。主要影响包括凝血活化标志物增加、凝血抑制剂减少以及获得性活化蛋白C抵抗。组织因子途径抑制剂（TFPI）减少可能是一个重要机制，它预示着凝血活化和对活化蛋白C的获得性抵抗。在早期药效学研究中，凝血标志物应用作中间或替代标志物，以评估与新配方相关的风险。
